You are here: Industry Insights > Takeda

News List

Sosei Heptares, Takeda Enter R&D Partnership contractpharma
August 06, 2019
Could be worth more than $1.2 billion and involves small molecules and biologics.
FiercePharmaAsia—Takeda's cost-saving progress; Dr. Reddy's shortfall fiercepharma
August 04, 2019
Takeda is “well on track” with its cost-cutting goal of saving $2 billion by the end of 2021 as it folds in Shire, Chief Financial Officer Costa Saroukos told investors.
PRA Health Sciences Buys Out Joint Venture in Japan contractpharma
July 25, 2019
Acquires expert staff members from Takeda.
Still on a cash-raising spree, Takeda shops €1.5B European drug sale fiercepharma
July 20, 2019
Takeda’s ax is about to fall again, this time on some over-the-counter and off-patent prescription drugs in Western Europe.
Takeda, Kyoto University research collaboration develops further biospectrumasia
July 18, 2019
iCART program advances the potential for a highly scalable, lower cost, off-the-shelf CAR T-cell therapy to treat cancer
Takeda announces results from Phase IIIb/IV clinical trial for ADYNOVATE biospectrumasia
July 08, 2019
The PROPEL study is a PROspective, randomized, multi-center study comparing the safety and efficacy of ADYNOVATE following PK-guided prophylaxis targeting two different Factor Eight (FVIII) through activity Levels in subjects with severe hemophilia A.
Novartis acquires ophthalmic drug from Takeda for $3.4bn pharmaceutical-technology
July 04, 2019
Novartis has acquired ophthalmic solution Xiidra (lifitegrast) 5% from Takeda Pharmaceutical for an upfront cash payment of $3.4bn.
Takeda Completes Sale of Xiidra® to Novartis americanpharmaceuticalreview
July 03, 2019
Takeda announced the completion of its sale of its Xiidra® (lifitegrast ophthalmic solution) 5% product to Novartis for $3.4 billion upfront in cash and up to an additional $1.9 billion in potential milestone payments.
Takeda selects new partnerships for annual CSR programme biospectrumasia
June 28, 2019
Takeda's contributions through its unique Global CSR Programme is total 10.5 billion yen for a total of 14 programmes since its 2016 launch
Takeda ditches late-stage Ninlaro trial pharmatimes
June 11, 2019
Takeda has announced the premature ending of its Phase 3 TOURMALINE-AL1 clinical trial in patients with relapsed or refractory systemic light-chain (AL) amyloidosis, due to the study not meeting the first of two primary endpoints.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page